Form 8-K

0001171843-24-000082.txt : 20240105 0001171843-24-000082.hdr.sgml : 20240105 20240105080018 ACCESSION NUMBER: 0001171843-24-000082 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240105 DATE AS OF CHANGE: 20240105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Compass Therapeutics, Inc. CENTRAL INDEX KEY: 0001738021 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39696 FILM NUMBER: 24514462 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-500-8099 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Olivia Ventures, Inc. DATE OF NAME CHANGE: 20180419 8-K 1 f8k_010524.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 5, 2024

_______________________________

Compass Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-39696	82-4876496
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

80 Guest Street, Suite 601

Boston, Massachusetts 02135

(Address of Principal Executive Offices) (Zip Code)

(617) 500-8099

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CMPX	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

Compass Therapeutics, Inc. (the “Company”) estimates that its cash, cash equivalents and marketable securities were approximately $152 million as of December 31, 2023. This amount is unaudited and preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company’s financial statements as of and for the year ended December 31, 2023.

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

The Company cautions readers that statements contained in this report regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include the Company’s estimated cash, cash equivalents and marketable securities as of December 31, 2023. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to, potential changes in estimated cash and cash equivalents based on the completion of financial closing procedures and release of final 2023 results, and other risks described in the Company’s filings with the SEC. The Company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Item 7.01. Regulation FD Disclosure.

On January 5, 2024, the Company issued a press release announcing updated program timelines, additional clinical data, change in management and year-end cash position. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release issued on January 5, 2024 titled “Compass Therapeutics Provides Corporate Update”
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Compass Therapeutics, Inc.


Date: January 5, 2024	By:	/s/ Neil Lerner
		Neil Lerner
		VP Finance

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Compass Therapeutics Provides Corporate Update

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Consistent with prior guidance, top line data from this study continue to be expected in the second half of 2024.
Enrollment of patients in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC), has been extended into the first quarter of 2024. We expect to report top-line data from this study by mid-year 2024.
Further evidence of clinical activity has been observed in the Phase 1b, monotherapy study of CTX-471. First, one patient with small cell lung cancer with a previously reported partial response has converted to a complete response, as confirmed by a PET scan, while continuing therapy on CTX-471. Second, in addition to the four responses previously reported, a new partial response has been observed in a patient with advanced melanoma, bringing the overall response rate (ORR) in patients with advanced melanoma in this study to 27% (3 of 11).
Following FDA acceptance of the CTX-8371 IND in late 2023, we expect to dose the first patient in 1Q 2024.
As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.
Effective January 9, 2024, Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors.
Ended 2023 with an estimated $152 million in cash and marketable securities, which is expected to provide cash runway for the company into mid-year 2026.

BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.

“We made significant progress in the fourth quarter of the year across our portfolio, and we look forward to reporting top-line data from COMPANION-003 by mid-year and COMPANION-002 in the second half of the year. We are also excited to report additional responses in our Phase 1b monotherapy study of CTX-471, including a complete response in a patient with small cell lung cancer. We hope to see additional efficacy signals in the second part of our Phase 1b study, where we are studying CTX-471 in combination with KEYTRUDA® in patients with melanoma, NSCLC and SCLC,” said Vered Bisker-Leib, PhD, incoming Chief Executive Officer of Compass.

“We are excited to have Vered Bisker-Leib elevated to the Chief Executive Officer role recognizing many years of strong performance. We are equally pleased that our founding CEO, Thomas Schuetz, will continue to play a key role at the Company,” said Carl Gordon, PhD, Chair of Compass’ Board.

Development Pipeline Updates:

CTX-009 (DLL4 and VEGF-A bispecific antibody)

We continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in BTC.
- This randomized Phase 2/3 study is designed to enroll 150 patients with BTC who have received one prior systemic therapy.
- The primary endpoint of the study is overall response rate (ORR), and secondary endpoints include progression free survival (PFS), overall survival (OS), clinical benefit rate (CBR) and duration of response (DOR).
- Enrollment is expected to be completed by mid-year 2024; top line data are expected from this study in the second half of 2024.
Enrollment of patients in COMPANION-003, a U.S. Phase 2 study of CTX-009 as a monotherapy in patients with advanced, metastatic CRC, has been extended to first quarter 2024.
- The study design is an Adaptive Simon Two-Stage, with Stage 1 of the study enrolling 37 patients; if 3 or more responses are confirmed in Stage 1, the study will advance to Stage 2, and an additional 47 patients will be enrolled.
- The study is enrolling patients with CRC who have received two or three prior systemic therapies irrespective of their KRAS mutation status.
- Patients are being evaluated for safety and tolerability, as well as clinical response.
- We expect to report top-line data from this study by mid-year 2024.

CTX-471 (CD137 agonist)

CTX-471 is a CD137 agonistic antibody, which binds to a unique epitope of the co-stimulatory molecule 4-1BB with an optimized affinity.
We continue to dose and follow patients in the Phase 1b monotherapy study of CTX-471 where five responses have been observed, all in patients who previously received checkpoint blocker(s). A durable PR in a patient with SCLC has converted to a CR, as confirmed by a PET scan. Additionally, a new PR in a patient with advanced melanoma, was observed, leading to an ORR in the subset of patients with advanced melanoma of 27% (3 of 11). The fifth response occurred in a patient with mesothelioma.
Phase 1b combination arm of CTX-471 and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with select solid tumors is ongoing. The dose-escalation portion of the study has been fully enrolled and enrollment in the dose expansion cohorts has begun. In the expansion cohort, we plan on enrolling 60 patients with melanoma, NSCLC and SCLC, who will be randomized into two doses.

CTX-8371 (PD-1 x PD-L1 bispecific antibody)

CTX-8371 is a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 and exhibits a unique mechanism-of-action that involves cleavage of cell surface PD-1.
Following the FDA acceptance of the IND for CTX-8371, the first patient is expected to be dosed in the Phase 1 clinical trial in the first quarter of 2024.

Corporate Highlights:

The Company’s CEO succession plan is effective as of January 9, 2024, with the elevation of Vered Bisker-Leib, PhD, to Chief Executive Officer and her addition to the Compass board of directors.
Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and current Chief Executive Officer will transition to President of Research and Development and assume the role of Vice Chair of the Compass board of directors.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Compass’s financial position to continue advancing its product candidates, expectations about cash runway, business and development plans, and statements regarding Compass’s product candidates, including their development and clinical trial milestones such as the expected trial design, timing of enrollment, patient dosing and data readouts, regulatory plans with respect to Compass’s product candidates and the therapeutic potential thereof. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Compass’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, Compass’s ability to identify additional product candidates for development, Compass’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of its product candidates, competition in the industry in which Compass operates and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Compass files with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov, including without limitation Compass’s latest Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Jan. 05, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 05, 2024
Entity File Number	001-39696
Entity Registrant Name	Compass Therapeutics, Inc.
Entity Central Index Key	0001738021
Entity Tax Identification Number	82-4876496
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	80 Guest Street, Suite 601
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02135
City Area Code	617
Local Phone Number	500-8099
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	CMPX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 8 f8k_010524_htm.xml IDEA: XBRL DOCUMENT 0001738021 2024-01-05 2024-01-05 iso4217:USD shares iso4217:USD shares 0001738021 false 8-K 2024-01-05 Compass Therapeutics, Inc. DE 001-39696 82-4876496 80 Guest Street, Suite 601 Boston MA 02135 617 500-8099 false false false false Common Stock, $0.0001 par value per share CMPX NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ= M%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6S MU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD M)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7? MZ/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U M$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( A M)5@D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.U MD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E. MGV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S M9)[NF:*'3^ 5!+ P04 M" (0"5899!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU. MPS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^> MEZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-X MJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB] MXY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TAD MIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_ MYHOA/UY_ 5!+ 0(4 Q0 ( A )5@'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ "$ E6!8&@O/M M *P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! M A0#% @ "$ E6)EWL$ V$0 M& @($," >&PO=V]R:W-H965T&UL4$L! M A0#% @ "$ E6)^@&_"Q @ X@P T ( !O0P 'AL M+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0# M% @ "$ E6"0>FZ*M ^ $ !H ( !XA$ 'AL+U]R M96QS+W=O9(9 0 MSP, !, ( !QQ( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& 2 D "0 ^ @ $10 end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_010524.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_010524.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "dts": { "inline": { "local": [ "f8k_010524.htm" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_010524.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_010524.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001171843-24-000082-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-000082-xbrl.zip M4$L#!!0 ( A )5B(V@&9J@\ )4J + 97AH7SDY,2YH=&W%6FES MVSBV_07S'S#I>5-VE5;'B;,XKF?+" MJTQIIFO>J^FJ=!0*!.YR[KD+=/KGR[O)T]_OI^+'IYMKJ:3_]9$>*1F> MG68ZB]39-%Q(>Z4CG2Q.A_[1::PR*0*39"K)/KW*U',VI%T^BF IK5/9I[5. M0K-V_?'1FZ-7HG@AD;'Z].KS]';Z1+OWP_&I\/BX>DPW?%Z )&4I??GD*]<09_[3O^N/HCQ<=K< M?F+B5#HGGI;*RE3EF0ZY$ID1)E6)". U'H>0,8<7S%Q,GG[% MTO?BX/+Z^E@\BU^FGZ_ZYV*F7:H"/=R0]J_.6NML*62XDDF [6; ME+0;D5D99"*@AU8<7#Q-#@>P&E#J"!S^I=1J8\4BUR$M@XPF%=!-"9A4BKDU M,<36KA"Q:8>9$NH98F4X$;*0CH^/!Z1 F/)U9@AP9M##J ME*T5DQQ8NVFGW39@0$,XN*@TP.1A M6"Z6 &R@\+\H3Q:EH;PA@0R(97(7;0JE<7 *TVC(9I5+ 23%LL'G*\5?PS[$ M7G$:*81EN:@G_"*8-R9T;K#H?OHD',[KB?521U6 @0I%J8=):@T>&5@]4ER& M(;.L*)UFMNX5\85K9M5 $J5F!R$\N>F%F(64@J#%0G*U:; M,B,=W#T\[(O07=$1$,@&("*=U$\RA@< U\DO%\<;XY[W /6\9.M0NB+ 5 M+*WF)O,LF)A-[W>*>>^$59:'ZAW7=E^]=* [;WR\N>*%G^'B:D,,B8 M32=W=Q!6$S21IZI%TE4?)TNMYF+ZK(*<#[R;@Q\!7WK['Z8(D7+QS$@;DGE" M3:Q@K-M)3+LU>%K"94X\!LM<9;_WQ,UE6X6__O#N:'SR$0O(C$S75R8'QWBA M=@G,6F95^4".J6T!D1^4 Y$$2][D4JU49-*XM!-86*8IU*7X^P7[X1BI;86$ M/ZX_K%C:[ZA$9A$G@=Q"$^4X MN"$W\%UE"BB7^@SN7[9YLI8;1+%E>8D\9++QG-SDT+N)+$@S$P:UTH?SM M@YC)UJ2HRV(9\$Z4:PKY0^\F"E&H MBR0+XP!*9?;NSR2]GS4+&^(SJV0FXCS*-"A4+/,8UD=T*:QVE)M#V2!C*6:Y M0PZ".CE70 ,J7]@DA,2CT4=DKEC"T@YE#\$1QY,X"TOO%!%"_ DW-[(>/66S MR\ :+"2"I2/G!F[OL;O!(I$QW\EM:P)6E1B9%E_FQE9.;Z5''^N-,FE'+5$* MQ>E86OR)G &L EV@JDC,97IH\#RK2DJ4^7)ONJ0D$T1Y2)IT)+..%-&=1EG0 M)8I%$LXIU91,4>3+8,..@2);.E.B(HE:,K.<%%&@4;(_V8"?D:"%[!R2)I[I M1#*3L'@_3?_^]/#U\ORO/XQ/CC^^3$IU8KM]G%Q/V"/TH<<@&G\43NIP)WO# M6"AB280=[$:6]4'7!4_2HN'$I<2;+XX2*E(K62QA5MMQ%DI*\E1@ /??2:B8 M8I%@XT@.7^2+5%G@-B8O56A2P'^$5 9G%Y&)0"3[SXG 6;_IWN\T/VLW&N3R/:T&J/9L>[>B/]KJC?YU#R3%U\'CH-$&==7T M+S!\+\'%F7Q6$7V-3F902?!$Y5.CE]K>&=^B6T2<>?@4$H[?C+;" )LBN H( M D-*4T'(-3.W2&Z#KBF&60KB&%19$[F$UL1$\.@H.!F7E%7)L*=.])3J8[^Y MARN82%6<3?:86W")R^U*K\ D!_=7C]B@W+U^?D>/JUYBIA(UUUEQZ.0"Q2F= M&>;6&QG25H(=7-X]'-;:-1JUK3P^4Q4]AB]:GH];G:0/].+E[7YI;_M8Y?HN MD?;WCFVPO80:0EFVDL'.BATM%C(XZ@"D:H%&LJN/A$G:':1O'VN@EG#P>"1S M(KV?AS)E$GO4D$0\K4W_T9<;+ !_%N,VGCR(B95>GU0"@]KG IV#A496-;(? MF;YNOZ!BL6>OL2,36:$L*>*7''EHRJ29O(Y/FC:*(AX$L$ J'"#)O!U];(5& M%0*UU&T;PYP=D9>MC>"BD/#>&8*:,KLE/8N"W=L(#/K3P_DCRJC,@YN\EKL: MT??EZ628F2*!D%ZBG#,,%:).SE6V8=4SD+B5-%#)-MS'KBG-4S];AE9IYWK_ M_XMYP5:9NU7Q;A$Y9?Z#R>488) +DVB7[:/LJE8@\+?>:G!^6;J#AD/G^_H\ MT;^!Y56J,ZIJ"D &ID_=08X6TX"[8M@KR)'XCOOCBXNJ@S" N*=GB52=P)@M MD9/HY-[FM\&X./?86<469-->K9B PP%H-/UP:1>VH7YKV#*& 8[!4 MP7=/[;/(!"A-#MSA0)PSAU+;<__041IR0=4Q(YD\[!N*8-LJW*)-.;[H/*!C M/+'&QK5^U#W[HIS\@'13D6V.-6T"W3&C("IN326H>X)MYUA=90T3H.NSG2.4 M6#ER%)J'6#:BL/1C,]FCEVIZD6!PHVSPO2B$'..S?W_9'U=CHJWR]B!5\0P\ MHW]'\S3KF,$X%),(383P^1>_<'L-CVQ05B8T$*LI M].UV_;*SC&=(ET3=*)3\V'/M(\Z]H)P.GN&1T@%;_UG@K^OQ'RT7JUV8?!*D M3K% :5)4(8W-&N&FDZ6>@7.L+\H=D4TF$^4#%&WU0L$&+!7I[.5B)SSSBZ[F MKE@%2PFFB_MFWJ?Y*DU;:%.=K$RT4D3K2JXH]=$D5OF*:H[VGO>OP5L/X,AE MW4,XFKU1-BEU[G5-VEY45.2,[0%OG6PR2P/,LG/O'%?O<&%]6_*C7BPCNLAQ M'W9XZ:GN6*K 0_L#6T!)7X4R($GZ:EHFN<5Z,3-C;#*NN8_Z[=\)5E2'_T>".F0W>^G\9X.'X//936.X8R3I_;(S7Z>_SFMLZ1-"J5-:=MEP08*F*R+5PMS?LH6:.^_M MCM,S5*U20,-1;LHTF9(_@@^6:[E!(ZM^R[4MZE :O=;Q19G/2U:5G"0;CZ1\ MFQA#E$@V,Q6*96M6T@7T/$=%M-*R98.^EX[2UH)R"0UT2)]B#V1RPW>%A96J M=,_[D&!4]K')O:20CFBSJM:\P"R&2E8:N"/@%VT%TB7V*<_B(XS+TY1;W56# MKIWP6-N4"9L:^15--DOOH>]5B$(_TRDQ323EB]>BL:%DT.$P]!@F7RQKF@V; M,4I11W4#R#V4$0T$ZO:#U.B:5S0!7V&F0#Z]Y[%/O0G4I>("VM87?]@T0:!5 MTJ!E:,.02CP>3/E4<30:^QD.D$>W^D5*\%]>&)?1@.D&%I$@0!1]&0+IJNP3 M=<+#,)*]![>"PEJ,T[I[7ZL9W7<+F?D^;YEEJ?LP'*[7ZT'@7VC&,SU[.;6Z M\C/C_K4QWXD[C >*)R) [A7D#IQY>RY'Q7[N&J?06// MZH:MO0MG?>K_T$.(%)&!4@*K@%_O FH>]NV?@\UW+R@C$CB/:>+(?0J)D2P0 M85;-X1S@D;&YS6AHCX!52O.IJ?-)U2%Y*--QW6#N%06%ISXA.0TT;EIZ]:4! M3X :2.=P*891M2I6+: D3T"W).TZO)Z=^TX\W,IV6Y5,K"-%\(0I')E4NK(& M+FHB7N79%'2M>=(,KJCKZUY52Z%RXID]:45--A))".79X(NR/_64P#%:# ZZ M?-#!$9P7EJJ9KPIN) GIJ3)S-&Y!EONA .B>&KP\@C@:W&C+KI\: 1SPC^J7 M$Q31>[ 4^KXX094 F@) I$_\!0C]OSH1Y[8+',(#CS)X,B%UK+XW::.?= M>NC-27>ZM:74[)_ZV# Q7$RAC_Z,44%9<4>4TQDJ\_Q0Y%K*W"!0GF+ZZ4U) MXMYBA?G\52UYU"ONRC)B#P:)#_DFT5?YW-!2+\&?M\G54TA]8T_UK0/10G/T M';*D-']G6=Q![CJYQS/ UF+$M2-J6R\W5(+\X7#[5P>J9^KD2-.J&$/A$@KHBN$FUOR43 BG\O.164G8Q%.U3$ M<_F3"BK9ZDUT6=BF/#O@6.#,$J+T]8XJK3XG8JV;+QZ#/U87\_SJ])FJJP6G M^EC[MN[@<3HY%.B =<1#+21)RNU.!8.%637IG;:FU!*!DXLYZW9HT*].T*"> M)PGYZ,$/0K$.!4 LQJ/^3SWQLZ]4D'Q??OVSMQ:-J="[([CG_%/)AE80MOA5 MP':-43J*?NZ6P:+MRD+;_]U1K;S8Z$:%J'2+741[&R@FQ6> S=B0B0&E**+= M)]X;F8"*K."5,>VR\TQ:\79\TG\S&O7?C=Z_9R&*7R_Z7R0.J6&BGVQF<73V M3U!+ P04 " (0"58%' AE@40 600 #@ &8X:U\P,3 U,C0N:'1M M[5M[.S>:<[-H^X[VD[I^4F!&@\\QH(FD,Y--? MMZ099F# V.OX+E67JNPN2.IN=?_Z)8FSORW"@#PRJ;B(/E1:]6:%L,@3/H^F M'RJ)GM1.*W\;G,TTS(*9D?I0F6D=]QN-^7Q>GW?J0DX;K5ZOUUC@G(J=U%^4 MSFLWFZW&+Y\_C;P9"VF-1TK3R&/9HH!'#]OIXV@V=2P#7IB*WZ1,.HT-TC#J MKQ;D)Q\W[&!AJBZ=>F2GZG0J5Z+;;IWLDL/.R!8LMLUMH?5M-U M^?S5U(:6-%(3(4.JP8)(Z:C6;-?:QSDB-<6\ B'X7)^*QR?IG-8ZK93.AG&* M.\7A,569QGVVINZ4)PS BG8GG2C99"O9XP:,IA,359M2&F>3)U2-S40W4* * MWTD1,%4ZVXS@]%:MV VC/J#,\UUP 8? M0;?DM/;36<-^/FO8T;'PET3I9< ^5"8B F/QWUF?M)JQ!@H^?TP'?:[B@"[[ M)!(1>P]C?-%'$DS:?W+?9Y'Y)TRX3D(FN4=$Y!/V>- KD!62-O ?.A B#KCP6HE483 M&B *5HS/0Q;Y\+_^&-!I.<./N&:=E_FAW3Q*5Z[&5K+Z6^:F(QG;C$^CH(*,5!)QJX\OH\N5,D)&52+9P,7 M/@RF!-*AC")2V"0WFE'0_R9%MR4S^DR2(,3M.EGP,5!V8:[!(-5"OG@WFQ3P MVTL6B9!'I93WWE612&-M$\7M-PH8MB[E8D8#EA0"3$CEE$(^Z<3Z/7%? MC(76(H20U(8OBS$I'[!PQ5A(H&U)?!]0[X' &J)$P/UL,"5GQUNK\3GW]0PC M7_,=L/GNF]9Q\[V3TOX9E['M(E_SQ9SQZ4SW@4\ U!"A-1KP:=0G'C@.D]F& MC'C')3MLF@U^N;ZZ'UZ2T?WY_7!TUHA?F7%S*^/1\.++W=7]U7!$SJ\OR?"7 MB[^?7_\P)!9GJF90!6H157^HRXUFI/][2"\E1D,O1Z(GK-+;=??W-V_)>?;1*J$1IIH04;,P\J1M#I$2-(Z.O /S\:2- 9B0O2, MX7@BN>9,D>'"F]%HRLBYIPD,MWJ=[G:QFZ\N-F8WY'O'8B$U.4@_,PJ1DRE- MV"/0(](,,_^P;V/1KN+'!Q(AR#CSZ7()=%A4*8'=K4FD0YM?R_'W(XT2*I?D MJ$HP,[\&%I^%S!>%S>WVR=J*/DEBJ",\:!%<[;JC2KUC4ZYPJ;Z&D7)%78@P MIDJ1^QGDV9@EFGNJ2JXBK[Y;9QO0>C)";D'1P7!! ;\H.X)'9C(3JHB*F8?% MFT]X1+A6!! /6)*'KV1 3<WWV.J>^[S\!-IJP>F01%TR 5&C2$YM3^FBR=SCL'BN=[\08\9O$#*! 2G-?TLB.\?["ON:QE@7]IXNKERKXAE][Y+\ MM%WKGIX<=[>)WM#R66C;QP+@J08"F)9N(!-)\B,D(N5SFZ_ =0MP.5Q7XIX\ M(!Z%7.$Q&D'[$:N&EU*[JM_51W4RA&95+$'DHHK)M:@?YC36,.%@)KDAP33 M\TA+QG25C!(.9CUN;AQ3?&W$?_W=7< _;^2]F$?E>_L>K":B]7U4=Y0<^T5" MQ]XXP(V\A9G<'(N6R? 9TBGU9HEB6JNG3GZV,++H^Q>/MT?:9KO5.7H#B[DL MG3H"^/FMA,WS&+QCN(!J5/-'1FXFX%1,'9(#$)J@U#9%&U>:B2AUY"<\YE7[ MP(.MND88G4M&MVOWN'6RKMO#[;;[)""ZFFWNBMI'S6;MM-GKO9W15@7@7Q70 M"5AL3!$9(:M04WE!@N4)@8Q-0>:\U5!JL!=6CF]IM&NAR7DQB+!;1S^^<2 M+$#=-SS"C):OKI_J4'2W3L8D( M@#FNPRC,,?VK_GX5^L[];I1K?TR5_JXY:VO9-W)1"K#!Q#X)#G2.+<@<5= M O;IMH^<4=?.*/!HXJ!U0BX^WI%VIUF'B82(:+QNL@<*F*4D5!0 M;,NCKZ-QX%KSY-HWB8)Y]C:K,@DY-6X[!C8(,YE2=B=38KF&L=FQOW/GTJ2Z%/9 M[MF'!/LEY13>O7=/W695!O=XRV]/E;T9\: ,4R\Y"WB68.W./H)):DKGT3*$ MFO= O>B(XGGZ.MU#K&MWCFK4Q5*_ "3-9QR^6<%MW\CT7 S ? #AQ@N*D@"2 M3[;6(9:M]M@8W)Q+AR#U2 OOH4J^;=;Q:I_$5))'&B2,Q/@:8%9ZTFC9/]\: M+Y+44G>('*>9Z1LSE E3Y;Q-5KR(?LP;$Q"4T;]CF MP+0' #XSQY5K/0AT-#0B+)5X:B7VG,14$9]->&1O'FR-VSPBFY=PJ[NW#CG M"ZZ3]Z;.32=SM\90(L%D-X!6I$P MR3Y1S,P"N5R'C==]W!0 ]M$0:M7P"I;(?,Z!->H^8G-$E630,\,Z "R-/.P= MJ&<>VN%D?,+I4^DKVUO[VRJ-S@'-*HT\$NM?:^'%?;8=>W/[S'(RWOJ\9NL) MQ>2HQW3*:F/)Z$-MS&"C ",:S.E2[7NP5"",,1$/4:XT"^T! M3\IOZ_,?2^4,P"*BZ0 7DG:]V:Z3.Z:20)L#V)N825<=@VG)Q\SJ%P)0B ,0 M$QR%S2V6<(MW7 .3 P3$=]^()0[BO*8GTBFZN06I MPE:DVQ3/[XEGMY/P 8)T]D05=8*QU!U<;CW&!MWO6X!6%4 D4Z-3)D1KPC(7XYGD. ;SV28@'TW)DJ#AK MP'#.U&G!Y='$Q@=I7BDZ]\RA"0,P3WEKY B??B@_Z)T/[Y7 ,"_"%NX]-21GZ0>D2SP'&X+ML8B,' MZ!',:V->G8Q04=N9NGL-5DH]C5C^\P/5UACTM#R/(G@$Q^?JP3)(P.02#6 ( M&PU#O@Y0*"P&0+,):%BZD ^HWQ)B %UX 8_*E$Y)\&^WS@FVC:O34I6,DY5] M,5QJ<\9?);'0>%N.$=& &Y>LZ<^0W5!AP;S[1UE##"(V@^7IW,"H.-U1U4PQ M8<%MRV?*DWR\*Y:B-RE;,AFO'EX85&[W%5>5Q5 T, P'"89L"#GHIG93:A?F MJZ[5!B>G#[ @6#KD('=\X$9 ?"8F=C,YF6WHT?2!H0SY&Q2L$6.SU,2('+1@ MQ*43^]K.@4EX@%K$A,>EEX3V5SQNC"W APF=:!?FFN:!);'QTMRR14"%F#Z M[-+J)B)KKQ&K!:MS/&V%>H685)$Y (TB*!T\DY*,[;&<$5-)H;#@(<-?'*$_ M^+;@,P[%(Q.883*M.I]%&X4T@JK6G*TBXK!LJ+'4;R&?VXJ1G(.KQMF-7%$8 MK'>TIM#8^ 8J #N*67[&QY!D>[UZ*ZVO"FD6IX( ^6R[5V&"%B 'J^OI/*/# M5ZQ8BFG[_Q7'U_E-S_C-JAL9Y>(&@,,943W;@0[\PVQQ6A518G^EQ!:S7WN] M5GVFP\H X7'6H*X'(ZX5*YUZ:^!]E\';N*#8\%1B?F3F%]J?M2Z)W-JN&M^( M.6N3+\9A'0[M\VV4J]7L%D2S?UZ(1S#_+;@H]%L0E"'YXXN:2_!B^P3N .L- M'ZMF3&(NSUV9WQP2_-$A\=V[Z,,-"^[\<\6E$M:D.GO_6KNR=V>CJ MA^OS^R]WP]W'1L5'^?8(!RH/7WRIG%GCC;+C$%I!MD M'WVHM'<_0_^*&]1N+_\;J-)[R?:3,S:)["O-&MT]E55YI5>\]A<:_?68]C3[ M[Y?]1][AU4DM?+&;/P=;3HXG)F2B8?/!WV/BC M;!T&@_\ 4$L#!!0 ( A )5B%)5>KL ( -4+ 0 9VYW+3(P,3DP M,3 Q+GAS9+56T6Z;,!1]WJ3]@\4[<6BT2HE(JZG5I$I9-ZVKM+?) 4.M&9O9 MIJ1_OVO "20D"K3ER5R?<^Z]YM@FO-YD'#U3I9D42R^83#U$121C)M*E]_C@ M?WFXN;OST/75IX^ACIYH1A PA%YZ3\;D"XS+LIR4LXE4*;Z83@/\^]OJH<)Y M-7"QX4S\[8,'\_D<5[,.>H#":T(2+JX&.S);3! MGW$]V8&R7NAE#64.&M,]G*;1))7/&"8 ?S%SP$+[*2'Y%IP0O:Y$FXD.6"MS M"(3@/L@W+SG5O=!ZJD-(1;F%IERNJ:"E+IFBDTAF@ SFTV :@ 4XS:@P7Z7* M;FE""@[%_"L(9PFCL8<,42DU]R2C.B<1/4<2_(/@"8D0TA #;FLB-I;G3"02 M A]"^XT72G+Z"XI'=O#X\^Y$ HO -Q(<["$6+[UZ:*5 N!*+:<($JS).ZR= M/KJ546%;A&%%"?$^N"51:!I_%U?5.%=4 Z]J806!AMA CI BPJ."#^/L2NFE M- &W5+O%<[OD)TU0M;L6U@=+3[,LYW8O5+$G19.E!W[PW2?Z YU-P"8.895/ M;*YJX?<7H\GK)(B*#E0.-C^(R)PJP\"KK1U>5\Z,I?]HI4$VC_80?H...5D/ M[1@HE+]CJRNK_Y8]@HV&]MAUWCLU>KM-TNZV.1'P[DAHWO>/C1#ZELH@<7 ( MG;H'ZAML):-*Z@3%OOF.Y]N0'USXLV"RT?&NTB%%[)9A6!&.-Z*(([=17WY] M#&X'OAVUT3KA+EU0G#YRF+&%3*ZBH[!(ED(HUZ&>+)-<2_CC+'[D3K/$PY? M^\'^6XU-.\*0A\G[W!CB6@V&_P%02P,$% @ "$ E6*_O:H%1" AV0 M !0 !G;G EFB9"$4:)!7;_[ZD/AS)XI7D;<)(>4AL^9 \]QR* MXI5(Y_,ONX@.7K"0A+.;X?CL?#C S.'-\+?%:+*8SF;#@52(!8ARAF^& MC ]_^?N?__29$O9\;7XMD<0#70^3USM);H9KI3;7GK?=;L^VEV=5T#C7K3P-U M*% $?_+2#XM04E-U@;0DUS*)Y!OWD4J4:V0T !'FW2B'CZ)]4;,$I?L"K@?G[V\/LT&I(^1(SO)5;(O"9SR//(+PIU\9JNDG9M<"K MFV'(MKJ%\=7Y^#RI_R\EC-IOM+^21!NJP_1*;2/AY\W;P,5&@$ASP4V(GY+& MU[H*X<=+/ I(A)GI@\-!UE QOD,MA"E/0[T,XUDK>'_>A\9& 8\0.9%TM;0# MQDE+HPA'2V/W273+1=^?*Z+T-(9)@??GQ;B:G$HM+^.T3^(5BJGZPYTR+U[F MK \31LQ@]TV_+?'&.X59@(.7'J8*ID?&9DCB9;9@:>%0@H; M&CID/-,O9=X 14M,DV:?,K -ZWTLZT>T?.U.-8PSW#';5\==9>6YV3: M1Z]]SI3N([!1HY29;+PV@J*VFLAPP$6 A9[6G+]RH5SB MX&:H1&P)V;%!4XJDO%\M%/>?)SO2IG=5B[RI;=8+:I--9?4!BZ!8+6Y]E"]% MBE^S2S-DB W[IDY49PE--H *\T;FD!47Y_WTXFEL(?Y6=N37Q_]W=/O#?B71 M099=?IQE/(HX2^A.OF>S1="R"O8=+"M/7 $[:DX'WH8R.(I]V# VU]5@(7#0 MS@HK_,EVYG?)#9@U.):]B2$2^V<$BD$LF]Q$- ]8.'M4BG36AF#LYIW+HQ82Q& M] %ON&@PH8CLA?85PI#D/[F5_)\Q$@H+NF^C^A&X%\+;.$/:?W(\41%(9S9& MJC;B'Z-[H;Z5-"3_7]W*OUAC2G5RL4&L5>^OXGMA 4 ;,N'GCS/A]L5,%'1H M[7TX%.F=%67FD!M_<^O&' O" QV3:.'#$;@7#M@X0]I??83VMRQHJWP&[9'N M1<9UCPQ]?=:L_RU31.WO",4_8N ^ MF88=HSJMMY4LJ+.C3#Z&TA#&KN*)]-B4TU?8'HC 5X M]RO>UXE^!.V!ZC;&H.R.N!#'7/0#D<9;LIPQGPN=+[W>K]ORF-]UNZG/*B]!-06 M[($US?Q!@QQEORG/21 (+&7VQ\0UKK/% N^!&1!KT )'*2_$[N(T"RYZ:<%% MO06.,E^(W>5I%ESVTH++^L=@CK+@$KNI?GDO'OD6>/H(@/LC_Q%G4'RG*7#& M+8GF7LP%?R'I9HL1YC8*M.RD!.FTUE6FH+R.4F-SS9D( MC.!N741T6]QCHJ"VCO+<;[H..E]S5GL/^1C5:8VM9$&=7:6K9I^1!(>'P\>= M5K;,$I344?KYNR!*\S%KFV.6W4&R;4/16"NTTU+#C$'9':6<"TZ)KQ5BX7<= MAR"(VC6OXCHM.$ 74OMMMBHTJST7V/0!K"?YR6(@LUE1W*]6T$@-XSNM?@-M MT 5':>81O9F4,1:G>E$IU2='[.1!7QREG OLQWJ@W(\OEH]F'RXP$AVA.JV[ ME2RHLZ,T\P=_%,A\K\9B'RTYA; M1QEE?I+=[OPU8B&&5W38D)T6&R0,:NXHTWP=V,)68W78I[$Z;#%6.\HT0,!VEB4?>T BC2:4>:F8-V.'UR^B].8Z:02);<"N#D MV;+RPY7+!!77JF\OT0,3:HB#7CA]>#IC"@OD*_*"OR*%,KYU7MA+],"+&N*@ M%TX7'BZWG@1(4J_Q%('(&O'GQ*P!X)7^8*" M.UU1?!MA$>IA\!^";]4ZV\A8)[RU0 \,@'F#1CA=.7R[>]U8G6ZMJW6A@NZ# M!7;2H/Z.=\I.?-\L-4GG!"Q G QG?:@P;:H N.TN1[M<:B."M+J)E@ZA:" M-)7JM".MR$.^?'*:)A>WN==>E@NX3FL/T 75=IH%S^,E)?X=Y:AVWE^ ]4#K M8[:@U$XSWR^(/8MXH_S]7' ?8_-@2![.R1;)5ZL*>F!/^SA X]QNQ4V^0C+Y MT1_4$L#!!0 M ( A )5AG4='PE@H )B% 4 9VYW+3(P,3DP,3 Q7VQA8BYX;6S- MG5UOX[@5AN\+]#\0[DT+C..) Q1(,-E%QI,4QF:3;.S9;;LH%K3$.$)DTJ#D MQ/[W)251ED@>24E1DG.1<<3W4"_%)R3U=?SEQ_TF1:^$9PFCEZ/3D\\C1&C$ MXH2N+T??%^.KQ6P^'Z$LQS3&*:/D,KR?3SY]/)__\^781/9,-'B=4UA>1D8J2M=CB M3L_/SR=%J9(:ROV*IVH?9Q-EIZY9E"8=^H:3++G("GNW+,)Y<3AZ=X- A?QM MK&1CN6E\.AV?G9[LLW@DCAX2_\HCR%E*'LD3*IIYD1^VXA!GR6:;2E/%MF=. MGNQF4LXG,GY"R1KG))8[.I<[.OV[W-%?JLVW>$72$9+*[X]SL%WGK;JJH(EK MLP^$)RR^IA]SK4=[LK_(,<__AP8TXYTW8T[\K$C?HQS?Z3% MP$L^=J0;D?\7V[EI^=V'UWY<4[GQ5GQJ623[G-"8Q,JDK*)C!"[V4$P,5=UU M[2QJU9O*T9QQL^V9J+>H,R/1R9J]3F*2B+JG9_+#6'XHFBU^^6/&Q QYMC'PH-^EVI M_O-EQTJ"I,9Q!U^) M'<=RYSZQ:31]PU-6 B8QF 2&EI/ _LC62=R:I$6Q!H[)W)CQS &Z%T/_9VV];G M*@X"FB$.P=FB&83J*$\<75&ZP^DCV3+>A4];YIH:FTD=EJ8F*$8LQD T2BTJ MQ9Z(^&4GSM@)3P^]4!A*UUP 5G4T-%E0=-B]@8#4F"X@0P!Y^2U'J_I"R>29K.V&:+:?^ 8A.[I@4VK/-B*H,B!K0' M,E-$H"HD'&RN7^7J7"R3!C:VH?<)CV&[BY]:'"Q"NL.!%!5A2,9Y(JEQ&Z*' M(4/IFA[ JLZ-)@N*&+LWD)52C@J]?TBN:3P(D5KG!Q#-IAV/2A0@'&UG?6@( MM4\P;I(LPFGIY49LRSJ:9]&Z!@2TJT-B"(,"!7('PE(&*&:*$*_ _(M@/@R7 MAM(/+(95.RJU+$!0=&]]F$B]%TAF.\Y;KN$9!Y8ZNRG;8[:^/POH@@"EQYQQ MU[:4MT#Q- -=TSS)#S=)2NYVFQ7AEL:9$E=L0.84$WIY$"P IG0&2AF2.E0* MO?2\NDM \SN\L8T0=IE; NPFVQ2T-0&18#4&T'#4(BGV0L1,C$P+2P]MMO, .* T.EV M"! D@E [RB=(D2$^ M,2D65O?\@;/7A$;PDAF2>P$&,&VE1M.&AX[=8!\_]8)8Q7D=:\I%>>\?B9+Y M&67:)NU#3*D)#Y*VL=[!I53[1.*!93E._YUL.T_$[6(O>%@-6R%I*<-#Q6:O M#Y@R!HD@'R?6%:[RAH;U53*MW-TKP!9;QU> &X5!0&!S9+X"7%X]*46NNUDR MR@D&1H1VL;-.MIBJ^[A1%D87FX:,'B[^KH7&QQ^RS.Z2/CPS"C\@8$I<]31D M3O6V7AY$CP.F]%XO9*C0>;H:+S-,9/;ANU'F;&;7[=03N2H(HG=U-\8TKJESMMJAZWBH+H_2YG.@F5%K7%CK%8L#2) MDCRAZY_%R2=/L*U5-I$K(&"#B@93$00*H"V=@Z,0*:5C"!XXD1 2T1'%2X R ML1"_?WJRSO9=8E=0]!M6<,#*("#IM:?#(@+&42,"E2&HB/&+S3S+=H2_"QY+ MB">$0/, 2(8^1)P@D[U0E8$^V5J0:"?FQ\/I=+5,\M1V6',NDJHO#9L52(/N45>4*@@Z+B@.+ M) @48%\Z#7<,55)4:GUDIVJ9M31'*W<%@-66ZOI681"=;G-D_/&W^MK3D'^] MCYZ%*0*\D&"7N1[Z;2;UX;^I"0*!#F/&24DE14KKXX6$XY2U[E\$K+TM M8] MBX!UB(N ]=!%P-K;(D#MMDP1(L:E^U6:K#&0G+!3[1J*#LLZ'Q9I4*C _L Q MHPY!QQC7&2V+%&=S^L3XIMC_C?A@:26@'^(,UH&FJ_!Z=&'P= PDP9.99C* M95@''E-=NKZ47CZ \1M)TY\H>Z,+@C-&25Q>2['=*>K6NWUBIL=V^Z$90!P$ M3D,< H_.R*#QBXQ"*JRZ$N:%I%]9NJ,YYL6[Y-PV,@$ZM^0 -MO$:** 2+$[ M PBIQ:A4^WE!N\P>42^RY(!G30'3+7?\NG:G:>VM;:LV(&8Z#4+O<%4M90R?B:76FG4\):ZIW">.,2R:N6-J24!XV'QU9)#A2&F]L+#8X#3]NLL2 M2C)X(M)4;EFP6FRST)($Q(+-%\!"(45*ZX6%ZPWA:S&]_8.SM_RYRL\*M@U0 MNV6CTW*;$:LT(%:Z_ ',J!!4QJB4NG[@V1\3BI=9%N&66J2.L0'-:LP8NI" M@-1)%$:)\10!@%2KSWX>TCJ"*1"'%-S+QCFS?.XPL0$QOP;8?^$%<$ M#36O..K3!T'30),Z4T58^^2Z"$0RTFWB)UQ(Y7AE;#&H+XX8B"$9 M6]"RN/E= 7YRY^U6:1+=I S#5UE:&L<9\TQ[6K*\HR @ DQ74(J\0H@*I9?^ M_XKI"]]M\^CPP%E$B'S**JM'J[[K;P.CW3+SKB:U:1H4&A!G[_$+$'BL C7J M^-28L7Q>S),/CR1/A\KV#)=GG7\6.7CK., ;$ MNCY[&]P<_62N-S ("-_K%CK5RU"S K22SXA55:#?926HJ,7V_>7-3;?BD]BL M-HD?*YP1L>6_4$L#!!0 ( A )5ALP4#5]P8 /96 4 9VYW+3(P M,3DP,3 Q7W!R92YX;6S-G-%RXC84AN\[TW=@Z#4A0-MM,ION)&SH,)O=I(%V MV][L"%L8362)D>P ;U_)!A:#)!]N?)*+A)A?]OF_8\L^MN3W']8I;[U2I9D4 M-^W>Q66[144D8R:2FW:N.T1'C+5;.B,B)EP*>M,6LOWA]Q]_>,^9>+FVOV9$ MTY99C]#7:\UNVHLL6UYWNZO5ZF(UN) JZ?8O+WO=?SX_3*(%34F'";N^B+9W MK>Q:7.UZ5U=7W>+;G?1$N9XIOMO&H+L+9[]F\RT+Z \BT>Q:%^$]R(AD!8[: MS;2\"OM?9R?KV$6=7K\SZ%VL==PV]%KFIR2H)*?/=-ZR?_]Z'N^WFG YHX*N M](HI>A')M&L5W:$TV3+A%FT7BLYOVHE8F2WTKBY[E\7Z?ZIHLLW2)$VS=,F- MS6YEVTM%-1598??!+*@TH>N,BIC&NQ79S9\57<8RV^*R_.FU.JV/,LI3LT'S ML51NH]G%PV54"8';5,@CNS8";4(H@&L:723RM1M39L#W!_9#QWXH0)A_OA4; MNIWI3)$HVZV)DQGEQ?J_&28 \>QA G6ZPB'ZD.E)L:;G4@*TH@7S[J'P=WAK&O#MVGFG";+PVE(FA M1.W"<+_@:0($/\#L*8)ND3)P*T1.^#-=2E4#OJH$\OX9D[?+&Q+F/W.B,JKX M!D+Z1 R$_0LF;(]#)-Y3181FE@\$^*D:2/Q7U L/CT)W>_S#8"_?[7G=W-J@;,_: +$_]M;P7_B%BD#3U0Q&9M3N@*P/Q$# MJ5]A4O!G1R"S38=P..10Y2LU9:Q,5 M^[^4*##T S$4.4H96F.Q8>##7*E*,,%>Q:^&(DS+;B64,4JM&3*'PGEH_"C"QR*F MZT]T$P)](H621JDQ@_904#\IEA*UF;"HOM,XU4)AHU2688,HM*=D/8Z-*S9G MY5/!>NC>)E#V*&4ER"Y*"L8BDFHI#VX7#V5NCL?-4,;!+KVF(30=*/7F&=91 MDG(;QP:7WOYY8(+V0JEPRL'/B/ 2$+#Y1K#WS\/>AV-'J4-K;;X1[(/SL _@ MV%%JT5J;F-B'YN.CFLJ5YPFT5PQ%CE*+UEC$!%Z<:1[5DY*OK!P<54?]I 44 M/6*)&C:+NL.7)WG(WKY30GDCEJMNNN)-UZ*'/$PC5DM.D; MC&7>[4T+WU"B(PF4+TJMZK33-%*;846)?_>M*J! 40I0EYF&>3Y(^^QC(47P M?NRI"LH5I9+TF6JZX[6CB;7WT#_X&CR"#:5;/;;1,,:OBF4F@J%,TUQL[]%X MGHIYI%"\*.5?T%[#J">2LXAE3"2?S16B8H2[.;MT4,@HQ9[?6,.$GQ2UF:;F MLKL8QV6G&ZC'^=S7\X;T4.(HM5Z]45SR8ZUSJL[E[V@%S0)*V0B%S:'UO NI[DS/[ M7I2*SV<*B6TY-MP<48\SSA+BGTD6; ">9X-)/&"UZ?E[Q92?L9A+E19QC,P' M-W:/% H<9XIDR%[3J/.8930N0QHQ041D2JK]O#9/=5[?"IH G#F40-,HM_>_ M4LX_";D2$TJT%#0N+_5#=_B]3:!90'R&6&,7)05_2YX;2JH8"*H\QX!'"D6. M^.S08P]G[&4YJ'E_[K$'H6^D?+@%%#SB0\2P6:3Q:1FU,;-7^I%D9!MAB+^O M!90_X@/%L%FT\?-J:$X\B0P_,S\20FDC#H5U6D.!/$D)YW>Y9H+J8-]R)(1" M1ASSZK2& OD^I2HQG=H?2JZRQ79N9PBVIP$4.N+(UJ!5'/CK[_/(R_EO0?(. M-?CM!(C8O2:Q7KL1178@17DF%S%1'NHA/90[ZL1*O]&&R3]F"ZH.KY^*8,:F M;@L->JAO!9)R8A2^_A$[X\V0$$$7 $T)8CUZ5DH<&X7R#2U MDXED]#)9&-/Z,<^*UWN:^((W#8+MH*G!G,0),(YT%:2_3_2B\=WFF^[)[X>S +[HMKR&_O+OHS5+/D?4$L! M A0#% @ "$ E6(C: 9FJ#P E2H L ( ! &5X M:%\Y.3$N:'1M4$L! A0#% @ "$ E6!1P(98%$ %D$ X M ( !TP\ &8X:U\P,3 U,C0N:'1M4$L! A0#% @ "$ E6(4E5ZNP M @ U0L ! ( !!" &=N=RTR,#$Y,#$P,2YX